MedWatch

Danish Anapa Biotech in pursuit of global money-spinner

Danish Anapa Biotech has streamlined its business to focus solely on a new molecular diagnostic technology. "We expect to sign one or more agreements with large companies in the foreseeable future," says the CEO.

Foto: Anapa Biotech, PR

Danish Anapa Biotech develops molecular tools for e.g. biotechnology and cancer. But now, the company has made a critical decision to focus exclusively on the company's newest technology that can be applied to various segments of molecular diagnostics - a market in the range of billions of dollars globally.

"We assessed that our newest developed technology has much more potential than what else we have been working with so far. Moreover, as a small firm, it's important to focus your effort," says Søren Morgenthaler Echwald, CEO of Anapa Biotech, to MedWatch.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier